LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Lista de Ações・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Fechado

SetorSaúde

21.45

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

Indicadores-chave
By Trading Economics
Rendimento	-1.6M -21M
Vendas	14M 54M
Margem de lucro	-39.611
Funcionários	178
EBITDA	-7.7M -26M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-3.62% downside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1B 2.2B
Abertura anterior	21.45
Fecho anterior	21.45

Day One Biopharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de jun. de 2026, 20:30 UTC

Ganhos

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Garth Brooks Considers Sale of Music Catalog, Seeking Roughly $2 Billion -- WSJ

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Brooks Had Been Entertaining a Deal for a Few Years, Sources Say -- WSJ

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Brooks Seeking About $2 Billion for Rights to Songs, Recordings, Sources Say -- WSJ

3 de jun. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Garth Brooks Considering Sale of Music Catalog, Sources Say -- WSJ

2 de jun. de 2026, 23:58 UTC

Conversa de Mercado

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de jun. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 de jun. de 2026, 23:41 UTC

Conversa de Mercado

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 de jun. de 2026, 23:01 UTC

Aquisições, Fusões, Aquisições de Empresas

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 de jun. de 2026, 23:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 de jun. de 2026, 22:57 UTC

Conversa de Mercado

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 de jun. de 2026, 22:50 UTC

Conversa de Mercado

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de jun. de 2026, 21:07 UTC

Conversa de Mercado

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 de jun. de 2026, 21:00 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

2 de jun. de 2026, 20:46 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:38 UTC

Ganhos

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 de jun. de 2026, 20:21 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:12 UTC

Ganhos

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Product Rev $594M

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 de jun. de 2026, 20:05 UTC

Ganhos

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

Comparação entre Pares

Variação de preço

Day One Biopharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

-3.62% parte inferior

Previsão para 12 meses

Média 20.75 USD -3.62%

Máximo 21.5 USD

Mínimo 17 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.